Nektar Therapeutics - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NKTR Nasdaq 2830 www.nektar.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nektar Therapeutics

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Feb 13th, 2026 2:15 pm
Why Nektar Therapeutics (NKTR) Is Up 102.2% After Strong REZOLVE-AD Data And $400 Million Raise - Feb 13th, 2026 3:09 am
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - Feb 11th, 2026 8:23 pm
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? - Feb 11th, 2026 6:08 am
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win - Feb 11th, 2026 5:42 am
Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 - Feb 11th, 2026 12:07 am
Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. - Feb 10th, 2026 2:07 pm
Nektar Therapeutics Announces Proposed Public Offering - Feb 10th, 2026 2:05 pm
Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study - Feb 10th, 2026 5:13 am
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing - Feb 10th, 2026 5:00 am
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 - Feb 9th, 2026 2:15 pm
Nektar Therapeutics (NKTR): A Bull Case Theory - Feb 2nd, 2026 8:02 pm
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 30th, 2026 2:10 pm
What Recent Price Target Signals For The Evolving Nektar Therapeutics (NKTR) Story - Jan 21st, 2026 10:09 am
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Jan 8th, 2026 7:36 am
5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Jan 7th, 2026 6:45 am
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks - Jan 7th, 2026 6:12 am
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - Jan 5th, 2026 3:05 pm
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - Dec 26th, 2025 12:33 am
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Dec 24th, 2025 8:51 am